P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-04-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000829588.31575.a9 |
| _version_ | 1797281075804766208 |
|---|---|
| author | P Sonneveld A Chanan-Khan K Weisel AK Nooka T Masszi M Beksac I Spicka V Hungria M Munder MV Mateos TM Mark MD Levin T Ahmadi X Qin W Garvin Mayo X Gai J Carey R Carson A Spencer |
| author_facet | P Sonneveld A Chanan-Khan K Weisel AK Nooka T Masszi M Beksac I Spicka V Hungria M Munder MV Mateos TM Mark MD Levin T Ahmadi X Qin W Garvin Mayo X Gai J Carey R Carson A Spencer |
| author_sort | P Sonneveld |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:51:18Z |
| format | Article |
| id | doaj.art-accd84a847664b2e877ffc158d3a69df |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:51:18Z |
| publishDate | 2022-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-accd84a847664b2e877ffc158d3a69df2024-03-03T05:10:28ZengWileyHemaSphere2572-92412022-04-016121210.1097/01.HS9.0000829588.31575.a9202204002-00027P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIALP Sonneveld0A Chanan-Khan1K Weisel2AK Nooka3T Masszi4M Beksac5I Spicka6V Hungria7M Munder8MV Mateos9TM Mark10MD Levin11T Ahmadi12X Qin13W Garvin Mayo14X Gai15J Carey16R Carson17A Spencer181 Erasmus MC Cancer Institute, Rotterdam, The Netherlands2 Mayo Clinic Florida, Jacksonville, FL, USA3 Department of Oncology, Hematology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany4 Winship Cancer Institute, Emory University, Atlanta, GA, USA5 Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary6 Ankara University, Ankara, Turkey7 Clinical Department of Haematology, 1st Medical Department, Charles University, Prague, Czech Republic8 Clinica São Germano, São Paulo, Brazil9 Third Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany10 University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain11 Department of Medicine, University of Colorado, Aurora, CO, USA12 Albert Schweitzer Hospital, Dordrecht, The Netherlands13 Genmab US, Inc., Plainsboro, NJ, USA14 Janssen Research & Development, LLC, Spring House, PA, USA15 Janssen Research & Development, LLC, Raritan, NJ, USA16 Janssen Research & Development, LLC, Beijing, China14 Janssen Research & Development, LLC, Spring House, PA, USA14 Janssen Research & Development, LLC, Spring House, PA, USA17 Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australiahttp://journals.lww.com/10.1097/01.HS9.0000829588.31575.a9 |
| spellingShingle | P Sonneveld A Chanan-Khan K Weisel AK Nooka T Masszi M Beksac I Spicka V Hungria M Munder MV Mateos TM Mark MD Levin T Ahmadi X Qin W Garvin Mayo X Gai J Carey R Carson A Spencer P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL HemaSphere |
| title | P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title_full | P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title_fullStr | P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title_full_unstemmed | P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title_short | P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title_sort | p04 daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone alone in patients with previously treated multiple myeloma overall survival results from the phase 3 castor trial |
| url | http://journals.lww.com/10.1097/01.HS9.0000829588.31575.a9 |
| work_keys_str_mv | AT psonneveld p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT achanankhan p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT kweisel p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT aknooka p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT tmasszi p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT mbeksac p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT ispicka p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT vhungria p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT mmunder p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT mvmateos p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT tmmark p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT mdlevin p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT tahmadi p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT xqin p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT wgarvinmayo p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT xgai p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT jcarey p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT rcarson p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT aspencer p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial |